Deka Biosciences

Deka Biosciences is an early-stage biotech pioneering a targeted cytokine therapy platform named Diakine™. The platform engineers single-chain fusion proteins that pair either two anti-inflammatory cytokines (for autoimmune/inflammatory diseases) or a stimulatory cytokine with an anti-inflammatory cytokine (for cancer) with a tissue-targeting scFv antibody fragment. This approach seeks to overcome the systemic toxicity and limited efficacy of traditional cytokine therapies by localizing potent immune modulation to the site of disease. The company is advancing a preclinical pipeline focused on major indications like Crohn's disease, psoriasis, rheumatoid arthritis, sepsis, and solid tumors.

The Diakine™ platform creates single-chain fusion proteins that combine a tissue-targeting scFv antibody fragment with paired cytokine payloads. For inflammatory disease, it pairs two anti-inflammatory cytokines (IL-10 & IL-4); for cancer, it pairs a stimulatory cytokine (e.g., IL-2) with anti-inflammatory IL-10 to localize and modulate immune activity in diseased tissue.

Deka competes in the crowded and rapidly evolving cytokine therapeutics space, facing companies developing engineered cytokines, cytokine-receptor agonists, and antibody-cytokine fusions (immunocytokines). Its differentiation lies in its specific dual-cytokine combinations and focus on simultaneous immune activation and suppression in oncology.